Article and Video CATEGORIES

Cancer Journey

Search By

What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?
Author
GRACE Videos and Articles

WCLC_2015_18_Treatment_Choices_EGFR_Acquired_Resistance_Without_T790M

 

Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Dr. West:  What’s your approach for patients with acquired resistance who do not have a T790m mutation? We’re going to be doing this testing routinely now, and we know that acquired resistance in patents with an EGFR mutation is mediated by this T790m mutation in about 50-60%, which leaves nearly half the patients without that option. Do you think these agents are appealing in this setting, and what would you do outside of a protocol setting for them. Ben, why don’t I start with you?

Dr. Solomon:  Yeah, so, with both compounds there are some data to suggest that there are patients who have biopsies that are reported as being T790m-negative may respond. Now, in part, that may represent that fact that the T790m result is a false negative, and that might be due to tumor heterogeneity, but there are responses seen, and the response rate with rociletinib, for example, is about 30%, but it is lower than within the T790m-positive. Off the study, I think my standard practice would be to use chemotherapy in those patients, but given that many of these patients will have tumor tissue available for testing, I think it’s worthwhile looking for other mechanisms of resistance. For example, MET or HER2 which might guide patients to a particular clinical trial that would benefit those patients. There was some interesting data that was presented in the presidential symposium today by Daniel Tan from Singapore, who sequenced a bunch of tumors from patients who had progressed, and in some of those T790m-negative patients, they found a high mutation load, which may predict that this subgroup of patients may be the group that might respond to immunotherapies, but that’s early days, and again, another hypothesis that we need to test and practice.

Dr. West:  Leora, what’s your approach for the T790m-negative folks?

Dr, Horn:  So, outside of a clinical trial, chemotherapy, or I do use afatinib and cetuximab in some patients. I do warn them that the rash could be a little bit more severe, but that is a, often, go-to regimen, especially for patients who are not wanting or are not ready to switch to chemotherapy.

Dr. West:  Right, it’s interesting, I mean, harkening back, it’s now data that are a few years old and have been slow to get corroborated, but the afatinib combination with cetuximab looked encouraging in, not just the T790m-positive, but the negative patients, but as you say, the toxicity issues can be pretty challenging there and we need to get more data in a larger setting than the initial reports were — but interesting.

Dr. Solomon:  Yeah, I agree, those data look good. In Australia, our issue is, neither of those agents are funded and I think it’s a very expensive combination for our patients to pay for.

Dr. West:  No question.

Dr. Horn: Definitely.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on